Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Feb 14, 2020; 26(6): 645-656
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.645
Table 1 Demographic and clinical characteristics, laboratory tests, and severity scores of patients on admission
CharacteristicAll patients (n = 1281)Without BI (n = 921)With BI (n = 360)P value
Median age (IQR) -yr51 (42-57)52 (43-57)50 (42-57)0.16
Male sex (%)1012 (79)726 (78.8)286 (79.4)0.88
Concomitant etiology of cirrhosis (%)
Alcohol142 (11.1)102 (11.1)40 (11.1)1.00
Others48 (3.7)36 (3.9)12 (3.3)0.74
HBeAg positive HBV (%)1421/1122 (37.5)298/794 (37.5)123/328 (37.5)1.00
Experience of anti-HBV treatment (%)1284/1176 (24.2)183/851 (21.5)101/325 (31.1)< 0.001
Decompensations (%)2
Ascites1099 (85.8)773 (83.9)326 (90.6)< 0.01
Jaundice534 (41.7)297 (32.2)237 (65.8)< 0.001
Gastrointestinal variceal bleeding336 (26.2)280 (30.4)56 (15.6)< 0.001
Hepatic encephalopathy190 (14.8)82 (8.9)108 (30)< 0.001
ACLF at admission (%)284 (22.2)130 (14.1)154 (42.8)< 0.001
Median value for laboratory tests (IQR)
Log10 HBV DNA (copies/mL)34.7 (3.1-6.1)4.8 (3-6.2)4.6 (3.1-5.7)0.33
Hemoglobin (g/L)103 (83-121)102 (82-119)107 (87-127)< 0.001
White cell count: × 109 cells/L4.7 (2.9-7.5)4.2 (2.7-6.1)6.9 (4.3-10.9)< 0.001
Platelet count: × 109 cells/L63 (40-102)60 (40-96)70 (42-117.5)< 0.01
International normalized ratio1.6 (1.3-2)1.4 (1.3-1.9)1.8 (1.5-2.6)< 0.001
Serum sodium (mmol/L)136 (131.2-139)136 (132.3-139.3)134 (129-137)< 0.001
Serum creatinine (mg/dL)0.8 (0.7-1)0.8 (0.7-1)0.8 (0.6-1.1)0.20
Aspartate aminotransferase (IU/L)67 (42-124)60 (40-107)97 (56.5-192)< 0.001
Alanine aminotransferase (IU/L)47 (30-97)42 (29-80)67 (37-185.8)< 0.001
Total bilirubin (mg/dL)3.4 (1.5-15.5)2.6 (1.4-8)10.9 (3-27.4)< 0.001
Serum albumin (g/dL)2.8 (2.5-3.2)2.9 (2.5-3.3)2.8 (2.4-3.1)< 0.001
Median value for severity scores (IQR)
Child-Pugh11 (9-12)10 (8-12)12 (10-13)< 0.001
MELD16.8 (11.8-25.5)14.8 (11.1-22.3)24.4 (17.1-30.2)< 0.001
Table 2 Characteristics of bacterial infection according to in-hospital outcome
CharacteristicAll patient (n = 1281)Survivors (n = 1101)Non-survivors (n = 180)P value1
Bacterial infection360 (28.1)247 (22.4)113 (62.8)< 0.001
Source of acquisition
Community-acquired76 (5.9)58 (5.3)18 (10)0.02
Healthcare-associated136 (10.6)89 (8.1)47 (26.1)< 0.001
Nosocomial infection162 (12.6)107 (9.7)55 (30.6)< 0.001
Single site
Pneumonia126 (9.8)75 (6.8)51 (28.3)< 0.001
Spontaneous bacterial peritonitis69 (5.4)47 (4.3)22 (12.2)< 0.001
Urinary tract infection29 (2.3)26 (2.4)3 (1.7)0.79
Spontaneous bacteremia16 (1.3)14 (1.3)2 (1.1)1.00
Skin or soft tissue infection9 (0.7)7 (0.6)2 (1.1)0.37
Others217 (1.3)15 (1.4)2 (1.1)1.00
Multi sites34 (2.7)20 (1.8)14 (7.8)< 0.001
Unknown site360 (4.7)43 (3.9)17 (9.4)< 0.01
Table 3 Univariate competing risk analysis of risk factors for in-hospital survival
ParametersWithout ACLF at admission
ACLF at admission
sHR (95%CI)P valuesHR (95%CI)P value
Age (yr)1.01 (0.99-1.03)0.221.02 (1.00-1.03)0.03
Male sex (%)1.37 (0.74-2.54)0.320.97 (0.59-1.60)0.91
Ascites (%)2.88 (1.05-7.93)0.041.11 (0.57-2.17)0.76
V Gastrointestinal variceal bleeding (%)0.65 (0.37-1.14)0.130.64 (0.22-1.81)0.40
Hepatic encephalopathy (%)0.96 (0.36-2.57)0.931.90 (1.28-2.83)< 0.01
Jaundice (%)5.10 (3.10-8.39)< 0.0012.45 (1.20-5.03)< 0.001
Bacterial infection (%)4.94 (3.08-7.94)< 0.0012.34 (1.52-3.59)< 0.001
Pneumonia (%)4.79 (2.86-8.03)< 0.0012.06 (1.39-3.05)< 0.001
Spontaneous bacterial peritonitis (%)4.05 (2.19-7.48)< 0.0011.49 (0.88-2.53)0.13
Urinary tract infection (%)0.94 (0.23-3.81)0.931.34 (0.67-2.68)0.41
HBeAg positive HBV (%)0.92 (0.56-1.54)0.761.08 (0.78-1.63)0.70
Log10 HBV DNA (copies/mL)1.04 (0.90-1.21)0.571.10 (0.96-1.25)0.18
White cell count (× 109 cells/L)1.11 (1.07-1.16)< 0.0011.04 (1.01-1.06)0.02
Total bilirubin (mg/dL)1.05 (1.03-1.06)< 0.0011.02 (1.01-1.03)< 0.01
Serum creatinine (mg/dL)1.87 (0.59-5.93)0.291.05 (0.96-1.15)0.25
International normalized ratio1.97 (1.56-2.49)< 0.0011.09 (0.93-1.29)0.31
Serum albumin (g/dL)0.41 (0.27-0.64)< 0.0010.63 (0.45-0.88)< 0.01
Serum sodium (mmol/L)0.91 (0.88-0.93)< 0.0010.98 (0.95-1.01)0.14
Table 4 Multivariate competing risk analysis of risk factors for in-hospital survival
ParametersEstimateStandard errorsHR (95%CI)P value
Without ACLF at admission
Bacterial infection1.18720.27083.28 (1.93-5.57)< 0.001
Total bilirubin at admission0.02920.01041.03 (1.01-1.05)< 0.01
Albumin at admission-0.76950.23570.46 (0.29-0.74)< 0.01
Sodium at admission-0.07380.01780.93 (0.9-0.96)< 0.001
ACLF at admission
Pneumonia0.62500.21061.87 (1.24-2.82)< 0.01
Hepatic encephalopathy0.54530.20681.73 (1.15-2.59)< 0.01
Total bilirubin at admission0.02770.00811.03 (1.01-1.04)< 0.001
Albumin at admission-0.71100.19450.49 (0.34-0.72)< 0.001